Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new collaborators and a revision of the study version. Notably, the detailed objectives and treatment phases related to pembrolizumab for metastatic castration-resistant prostate cancer have been removed.SummaryDifference45%
- Check30 days agoChange DetectedThe page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding dates of January 20, 2025, and March 13, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version release and the most recent update date, indicating a shift in the versioning and timing of the content.SummaryDifference0.3%
- Check52 days agoChange DetectedThe webpage has updated its date references, adding new dates in March 2025 while removing older dates from January 2025.SummaryDifference0.4%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.